GP73、AFU及AFP联合检测在原发性肝癌诊断中的应用

Diagnosis of Primary Hepatocellular Carcinoma by Combined use of Golgi Protein 73,α-L-fucosidase(AFU) and AFP

目的探讨高尔基体蛋白73(GP73)、α-L-岩藻糖苷酶(AFU)及甲胎蛋白(AFP)三种血清标志物联合检测在原发性肝癌(HCC)早期诊断中的临床意义。方法将研究对象分为原发性肝癌组、乙肝肝硬化组、慢性乙型肝炎组和健康人群组,均采用酶联免疫吸附法检测血清中GP73、AFU及AFP的含量,并对各组结果进行统计学分析。结果原发性肝癌组AFP、GP73及AFU水平均明显高于后3组,原发性肝癌组AFP、GP73及AFU阳性率分别为64.58%、83.33%、75.00%,三种血清标志物联合检测HCC阳性率达95.83%,显著高于各指标单独检测,经统计学分析差异有统计学意义(P<0.05)。结论 GP73、AFU及AFP联合检测可明显提高HCC诊断价值。

Objective To explore the clinical significance of Golgi protein 73 （GP73）, α- L - fucosidase （AFU） and Fetoprotein （AFP） in the early diagnosis of primary hepatocellular carcinoma （PHC）. Methods The subjects were divided into four groups, group of PHC, group of liver cirrhosis, group of chronic hepatitis and group of the healthy. ELISA was used to detect the serum level of GP73, AFP and AFU of each group. Then a statistical analysis was made based on these results. Results The level of serum GP73, AFP and AFU in the group of HCC were significantly higher than those of the other three groups. Positive rates of AFP, GP73 and AFU in PHC group were 64. 58%, 83.33% and 75.00%. HCC positive rate detec- ted by the three kinds of serological markers was 95. 83%, significantly higher than the index independently tested （P 〈 0. 05）. Conclusion GP73, AFU and AFP determination can improve the diagnostic value of HCC.